Gilles Dosin1, Fouad Aoun2, Elie El Rassy3, Tarek Assi4, Philippe Lewalle5, Jeremy Blanc5, Roland van Velthoven1, Dominique Bron5. 1. Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. 2. Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Department of Urology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. 3. Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. Electronic address: elie.rassy@hotmail.com. 4. Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. 5. Department of Hematology-Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Abstract
INTRODUCTION: Hemorrhagic cystitis (HC) is a well-recognized problem that is regularly observed after hematopoietic stem cell transplantation (HSCT). The published data does not report on the potential risk factors for the viral-induced HC that might require prophylactic treatments. PATIENTS AND METHODS: We conducted a retrospective analysis of all adult patients who underwent allogeneic HSCT at Jules Bordet Institute between 1992 and 2013. Our institutional protocol consists in monitoring the patient for signs and symptoms of HC on a daily basis during the initial admission for HSCT, then once weekly after discharge until 2 months thereafter. RESULTS: HC was found in 64 patients, of whom 56 (87.5%) had viral-induced HC. The median time between HSCT and HC was 39.5 days (range, 1-2766 days); the median time between detection of a viral infection and HC was 32 days (range, 0-2752 days). In multivariate analysis, HC is correlated to the infection with the BK virus (hazard ratio, 6.0; 95% confidence interval, 5.03-6.90; P = .0001) and the adenovirus (hazard ratio, 4.93; 95% confidence interval, 4.06-5.80; P = .0003). The 5-year overall survival of patients with HC was 36%. The 5-year survival rates were not statistically different between patients with or without HC (25% vs. 39%; P = .20). CONCLUSION: The presence of the identified risk factors should prompt closer follow-up with screening tests and preventive measures for BK virus and adenovirus infections in patients undergoing HSCT.
INTRODUCTION:Hemorrhagic cystitis (HC) is a well-recognized problem that is regularly observed after hematopoietic stem cell transplantation (HSCT). The published data does not report on the potential risk factors for the viral-induced HC that might require prophylactic treatments. PATIENTS AND METHODS: We conducted a retrospective analysis of all adult patients who underwent allogeneic HSCT at Jules Bordet Institute between 1992 and 2013. Our institutional protocol consists in monitoring the patient for signs and symptoms of HC on a daily basis during the initial admission for HSCT, then once weekly after discharge until 2 months thereafter. RESULTS: HC was found in 64 patients, of whom 56 (87.5%) had viral-induced HC. The median time between HSCT and HC was 39.5 days (range, 1-2766 days); the median time between detection of a viral infection and HC was 32 days (range, 0-2752 days). In multivariate analysis, HC is correlated to the infection with the BK virus (hazard ratio, 6.0; 95% confidence interval, 5.03-6.90; P = .0001) and the adenovirus (hazard ratio, 4.93; 95% confidence interval, 4.06-5.80; P = .0003). The 5-year overall survival of patients with HC was 36%. The 5-year survival rates were not statistically different between patients with or without HC (25% vs. 39%; P = .20). CONCLUSION: The presence of the identified risk factors should prompt closer follow-up with screening tests and preventive measures for BK virus and adenovirus infections in patients undergoing HSCT.
Authors: Hannah Imlay; Hu Xie; Wendy M Leisenring; Elizabeth R Duke; Louise E Kimball; Meei-Li Huang; Steven A Pergam; Joshua A Hill; Keith R Jerome; Filippo Milano; W Garrett Nichols; Phillip S Pang; Hans H Hirsch; Ajit P Limaye; Michael Boeckh Journal: Blood Adv Date: 2020-02-25
Authors: Cesar Homero Gutiérrez-Aguirre; Alejandra Celina Esparza-Sandoval; Alain Palomares-Leal; José Carlos Jaime-Pérez; David Gómez-Almaguer; Olga Graciela Cantú-Rodríguez Journal: Hematol Transfus Cell Ther Date: 2020-12-04